pfizer.com (PFE) Company Sales Volume

Pfizer Inc. (PFE) sales figures demonstrate demand dynamics amid the decline of COVID-19 vaccines and a pivot toward oncology drugs. The 63.63 level reflects current sales volume. The current rise in share prices is based on synergy with Seagen and cost optimization. Business stability relies on M&A deals to replace expiring patents and FDA approvals for new drugs.

PFE Pfizer Inc Company Revenue (07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Pfizer (PFE)

- market value and analyst target forecast:

Market Chart Pfizer Corp|PFE - Price Target Chart

- market capitalization details:

Market Capitalization Pfizer Inc.|PFE - Enterprise Value

- issuer book value statistics:

Book Value of One Share Pfizer|PFE - Company Book Value|Market Capitalization to Net Assets pfizer.com|PFE - Company Total Assets

- debt and solvency information:

- earnings and multiples data:

PFE - Net Income|Expected Net Income Pfizer Inc.|PFE - P/E Multiple|Market Cap to Projected Earnings pfizer.com|PFE - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Pfizer Inc.|PFE - Operating profit EBITDA|Net earnings per share for the last 12 months Pfizer|PFE - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months pfizer.com|PFE - Earnings per share growth in current year|Net earnings per share change forecast for next year Pfizer Inc.

- sales volume and revenue indicators:

PFE - Revenue and Sales Volume|Company Expected Revenue Pfizer Corp|PFE - P/S Multiple|Market Cap to Future Revenue Ratio Pfizer Inc.

General company analysis:Pfizer Corp (PFE)

Manufactured products of Pfizer Corporation

This indicator captures the actual cash inflow from product sales, excluding any accounting estimates. It allows for an objective assessment of long-term revenue dynamics and business growth rates. By analyzing the sales statistics of Pfizer Inc. (PFE), an investor can see the resilience of demand for the company's diversified drug portfolio. However, the risk of patent expiration necessitates the constant renewal of assets through acquisitions. This makes the metric a key tool for monitoring the operational stability of the issuer.

Key competitors